As the world population aged 65+ increases; families, caregivers and medical personnel encounter unique challenges when providing support to the elderly. As this aging population grows, the number of people bedridden from illness or age has also grown. Bedridden individuals are at risk for developing complications from their immobility, including pressure ulcers. Pressure ulcers (also known as pressure injuries) are a major concern for the well-being of at-risk individuals. If left untreated, pressure ulcers can lead to serious infections, pain, or even death.
In addition to regular physical therapy and good hygiene practices, nutritional supplements are often used for the intervention or prevention of pressure ulcers. Protein supplements, such as those containing collagen peptides, can help maintain dietary protein levels. In addition, the key dipeptides found in Wellnex collagen peptides have been shown to support healthy skin function.*
A double-blind, placebo-controlled trial demonstrated Wellnex collagen peptides’ positive effect on stage II and III pressure ulcers after 16 weeks with regular therapy. Seventy-five percent of the subjects consuming Wellnex collagen peptides reported significant improvement in their sores, while 81% of the placebo group reported some or no improvement.
Animal studies have shown promising effects of Wellnex collagen peptide ingestion in relation to hypertension. Wellnex collagen peptide supplementation has been found to have an effect on angiotensin-converting enzyme (ACE), which is a factor for hypertension. Collagen peptides also appear to promote elasticity of the blood vessel endothelium.
To prove these theories, researchers examined collagen peptides on spontaneously hypertensive rats (SHRs). During the 12-week feeding period, drinking-fluid consumption calculated from the weights of the fluid bags ranged from 30-70ml/rat/d, with an average of 50ml/rat/d. These factors were consistent for both the control and test groups.
The systolic blood pressure of the collagen peptide feeding group was significantly (P<0.05) lower than that of the control group. Systolic blood pressure at the end of the 12-week feeding was 216.0±3.2mmHg for the control group and 206.6±2.9mmHg for the test group.
*These statements have not been evaluated by the Food and Drug administration. This product is not intended to diagnose, treat, prevent, or cure any disease.